Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies



The approach allowed the researchers to enroll a large number of participants in the study, from across the US.

Share this!

March 22, 2017 | by Sarah Hand, M.Sc.

Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones. The study investigators published their results in the journal, Nature Biotechnology.

The approach allowed the researchers to enroll a large number of participants in the study, from across the US. In addition, the app allowed study investigators and app users to securely exchange data, and allowed to investigators to collect additional information including device data, air quality and geolocation.

“The Asthma Mobile Health study represents the coming together of academia and industry to benefit from the ubiquity of smartphones and harness the power of citizen-science to modernize the clinical research process,” said Dr. Eric Schadt, senior study author and Founding Director of the Icahn Institute for Genomics and Multiscale Biology. “We now have the ability to capture rich research data from thousands of individuals to better characterize ‘real world’ patterns of disease, wellness, and behavior. This approach provides a more comprehensive and accurate view of our patients that was not feasible in the past due to logistical limitations and prohibitive costs.”

Upon its release in March 2015, the Asthma Health app was downloaded by US residents from the Apple App Store over 40,000 times in the first six months. Of this number, 7,593 people completed the enrollment process.

In addition to initial surveys meant to establish asthma history, comorbidities and demographics, patients were prompted to complete daily surveys including asthma symptoms, medication adherence and triggers for flare-ups. The researchers reported a high response rate with 85 percent of participants completing at least one of the surveys.

Just over 2,300 users were considered to be the most robust patients as they completed multiple surveys during the six-month study. To validate this patient-reported data, the researchers compared to results to other asthma studies.

“We critically assessed the feasibility, strengths, and limitations of a smartphone-based study and found that this methodology is particularly suitable for studies of short duration that require rapid enrollment across diverse geographical locations, frequent data collection, and real-time feedback to participants,” said principal investigator Dr. Yvonne Chan, Director of Digital Health and Personalized Medicine at the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai. “Our study demonstrates the power of mobile health tools to scale and accelerate clinical research so that we can derive the evidence needed to inform clinical practice and improve patient care.”

Mobile health studies and virtual clinical trials are an emerging trend in the healthcare and pharmaceutical industries. Provided that data collected from these studies is of high quality, they could present a number of benefits over traditional clinical research, including reduced patient burden and improved ability to reach global participants.

“Mount Sinai has a long history of embracing new technologies to enhance patient care, and I’m delighted to see that tradition continuing with this mobile health study,” said Dr. Dennis S. Charney, the Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai. “We look forward to building on this work to serve new patient populations and to dramatically increase the amount of research data we can mine for discoveries that will ultimately improve healthcare for people around the world.”

Keywords: Mobile Health, Virtual Clinical Trials, Asthma


Share this with your colleagues!

Kite Pharma Secures FDA Approval for CAR-T Immunotherapy

October 20, 2017 - Kite Pharma’s Yescarta (axicabtagene ciloleucel) has become the second CAR-T immunotherapy to be approved in the US, with an indication in treating adult patients with relapsed or refractory large B-cell lymphoma.

Featured In: Biotech News

Fallopian Tubes Found to be Site of Origin for Most Ovarian Cancers

October 20, 2017 - This year, over 22,000 women will be diagnosed with ovarian cancer but a new study conducted by researchers at Perlmutter Cancer Center at NYU Langone Health suggests that most of these malignancies begin in another part of the reproductive system: the fallopian tubes.

Featured In: Life Science News

Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Brexit – Separating Fact from Fiction

Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond

Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms

Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution

Copyright © 2016-2017 Honeycomb Worldwide Inc.